| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo … SM Maira, F Stauffer, J Brueggen, P Furet, C Schnell, C Fritsch, ... Molecular cancer therapeutics 7 (7), 1851-1863, 2008 | 1366 | 2008 |
| In vivo antitumor activity of NVP-AEW541—a novel, potent, and selective inhibitor of the IGF-IR kinase C Garcı́a-Echeverrı́a, MA Pearson, A Marti, T Meyer, J Mestan, ... Cancer cell 5 (3), 231-239, 2004 | 659 | 2004 |
| The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob, A Loo, P Furet, ... Nature 543 (7647), 733-737, 2017 | 572 | 2017 |
| Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ... Cancer discovery 7 (3), 252-263, 2017 | 530* | 2017 |
| Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor … V Guagnano, P Furet, C Spanka, V Bordas, M Le Douget, C Stamm, ... Journal of medicinal chemistry 54 (20), 7066-7083, 2011 | 530 | 2011 |
| Strategies toward the design of novel and selective protein tyrosine kinase inhibitors P Traxler, P Furet Pharmacology & therapeutics 82 (2-3), 195-206, 1999 | 525 | 1999 |
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials C Fritsch, A Huang, C Chatenay-Rivauday, C Schnell, A Reddy, M Liu, ... Molecular cancer therapeutics 13 (5), 1117-1129, 2014 | 521 | 2014 |
| Protein kinases as targets for anticancer agents: from inhibitors to useful drugs D Fabbro, S Ruetz, E Buchdunger, SW Cowan-Jacob, G Fendrich, ... Pharmacology & therapeutics 93 (2-3), 79-98, 2002 | 467 | 2002 |
| Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation P Furet, V Guagnano, RA Fairhurst, P Imbach-Weese, I Bruce, M Knapp, ... Bioorganic & medicinal chemistry letters 23 (13), 3741-3748, 2013 | 455 | 2013 |
| Tyrosine kinase inhibitors: from rational design to clinical trials P Traxler, G Bold, E Buchdunger, G Caravatti, P Furet, P Manley, ... Medicinal research reviews 21 (6), 499-512, 2001 | 426 | 2001 |
| Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1 J Schoepfer, W Jahnke, G Berellini, S Buonamici, S Cotesta, ... Journal of Medicinal Chemistry 61 (18), 8120-8135, 2018 | 412 | 2018 |
| Different susceptibility of protein kinases to staurosporine inhibition: kinetic studies and molecular bases for the resistance of protein kinase CK2 F Meggio, AD Deana, M Ruzzene, AM Brunati, L Cesaro, B Guerra, ... European Journal of Biochemistry 234 (1), 317-322, 1995 | 362 | 1995 |
| Imatinib: a selective tyrosine kinase inhibitor PW Manley, SW Cowan-Jacob, E Buchdunger, D Fabbro, G Fendrich, ... European journal of cancer 38, S19-S27, 2002 | 351 | 2002 |
| Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia SW Cowan-Jacob, G Fendrich, A Floersheimer, P Furet, J Liebetanz, ... Acta Crystallographica Section D: Biological Crystallography 63 (1), 80-93, 2007 | 332 | 2007 |
| Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 C Garcia-Echeverria, P Chene, MJJ Blommers, P Furet Journal of medicinal chemistry 43 (17), 3205-3208, 2000 | 331 | 2000 |
| New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis G Bold, KH Altmann, J Frei, M Lang, PW Manley, P Traxler, B Wietfeld, ... Journal of medicinal chemistry 43 (12), 2310-2323, 2000 | 331 | 2000 |
| Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines P Traxler, G Bold, J Frei, M Lang, N Lydon, H Mett, E Buchdunger, ... Journal of medicinal chemistry 40 (22), 3601-3616, 1997 | 320 | 1997 |
| Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking E Vangrevelinghe, K Zimmermann, J Schoepfer, R Portmann, D Fabbro, ... Journal of medicinal chemistry 46 (13), 2656-2662, 2003 | 293 | 2003 |
| Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode J Rahuel, B Gay, D Erdmann, A Strauss, C García-Echeverría, P Furet, ... Nature structural biology 3 (7), 586-589, 1996 | 288 | 1996 |
| Extended kinase profile and properties of the protein kinase inhibitor nilotinib PW Manley, P Drueckes, G Fendrich, P Furet, J Liebetanz, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1804 (3), 445-453, 2010 | 265 | 2010 |
